Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
TAK · NYSE · United States · Pharmaceutical Preparations
In shortTAKEDA PHARMACEUTICAL CO LTD is profitable, generates cash and carries moderate debt, with revenue growing (+7.5% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 7.5% | 42/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 2.4% | 29/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 1.5% | 8/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 1.8% | 12/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.01× | 17/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.65× | 75/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 3.74× | 7/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 1.63× | 1/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.44 | 9/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 18.7% | 95/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 7.93× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 6.2% | 88/100 |
| Operating margin volatility | 4.4% | 69/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 8.7% | 65/100 |
|---|---|---|
| EPS growth, 3-year average | -22.8% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
4 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
JPY millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 3,197,812 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,551 |
| Cost of revenue | 994,308 | 1,106,846 | 1,244,072 | 1,426,678 | 1,580,217 |
| Gross profit | 2,203,504 | 2,462,160 | 2,783,406 | 2,837,084 | 3,001,334 |
| Research & development | 455,833 | 526,087 | 633,325 | 729,924 | 730,227 |
| Operating income | 509,269 | 460,844 | 490,505 | 214,075 | 342,586 |
| Interest expense | 248,631 | 166,607 | 169,698 | 219,850 | 210,065 |
| Pre-tax income | 366,235 | 302,571 | 375,090 | 52,791 | 175,084 |
| Income tax | (9,936) | 72,405 | 58,052 | (91,406) | 66,941 |
| Net income | 376,005 | 230,059 | 317,017 | 144,067 | 107,928 |
| Diluted EPS | ¥238.96 | ¥145.87 | ¥201.94 | ¥91.16 | ¥67.23 |
| Diluted shares (millions) | 1,574 | 1,577 | 1,570 | 1,580 | 1,605 |
4 older years available with the 10-year history. Essential plan, from €8.25/month →
1.44 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Mar 31, 2026 · Data updated Jun 25, 2025